Vectorious Medical Technologies
Tel Aviv
About Vectorious Medical Technologies
Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy. The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. It monitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration. Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $19.1M
- Funding stage: M&A
- Last round: Series B (Jul 2018)
- Website: vectoriousmedtech.com
Industries & Categories
Health Care, Information Technology, Medical, Medical Device, Wireless
Social Profiles
Canonical: https://fsome.com/organization/vectorious-medical-technologies-84442 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.